Zabofloxacin versus moxifloxacin in patients with COPD exacerbation: a multicenter, double-blind, double-dummy, randomized, controlled, Phase III, non-inferiority trial

A new quinolone, zabofloxacin, has now been developed; hence, a non-inferiority trial is needed to compare this new compound with another widely used quinolone to examine its efficacy and safety for the treatment of chronic obstructive pulmonary disease (COPD) exacerbations. This was a prospective,...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Int J Chron Obstruct Pulmon Dis
Main Authors: Rhee, Chin Kook, Chang, Jung Hyun, Choi, Eu gene, Kim, Hyun kuk, Kwon, Yong-Soo, Kyung, Sun Young, Lee, Ji-Hyun, Park, Myung Jae, Yoo, Kwang Ha, Oh, Yeon Mok
Format: Artigo
Jezik:Inglês
Izdano: Dove Medical Press 2015
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4622522/
https://ncbi.nlm.nih.gov/pubmed/26543359
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S90948
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki